logo
Share SHARE
FONT-SIZE Plus   Neg

Dendreon Swings To Profit, Revenue Misses; Shares Plunge 18%

Dendreon Corp. (DNDN) Monday posted a profit for the fourth quarter, helped mainly by a gain from sale of interest in Victrelis royalty. However,revenues for the quarter fell short of analysts' estimates, sending the company's shares down over 18 percent.

Dendreon's results for the fourth quarter were boosted by the $125 million payment received on the sale of Victrelis royalty interest. Victrelis is approved for the treatment for chronic hepatitis C.

Revenues for the quarter surged to $202.15 million from $25 million last year. Meanwhile, product revenues, which exclude royalty and other revenues, grew to $77 million from $25 million last year, but fell short of analysts' estimate of $120.80 million.

The Seattle, Washington-based Dendreon's profit for the quarter was $38.1 million or $0.26 per share compared to loss of $91.83 million or $0.64 per share last year. On an adjusted basis, net income was $0.45 per share compared to loss of $0.50 per share last year.

On average, 21 analysts polled by Thomson Reuters expected the company to report loss of $0.23 per share. Analysts' estimates typically exclude special items.

DNDN is currently trading on the Nasdaq at $12.21, down $2.71 or 17.24%. Trading volume for the day is 24 million shares, above the three-month average volume of 9 million.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Ford Motor Co.(F) reported a profit for the second-quarter that declined 8.8 percent from last year, while total revenue increased about 6 percent. The company now sees risks challenging achieving 2016 guidance. ConocoPhillips on Thursday reported a loss for the second quarter that widened from last year, reflecting lower revenues and one-time charges. The results for the quarter missed analysts' estimates. However, the company raised its production outlook for the full-year. Like other companies in the oil industry, ConocoPhillips is struggling with lower oil prices. Bristol-Myers Squibb Co. on Thursday raised its earnings forecast for fiscal 2016 after reporting a significant profit in its second quarter, compared to prior year's loss. The results reflected the absence of prior year's hectic charge as well as strong revenue growth. Earnings per share and top line beat market estimates.
comments powered by Disqus
Follow RTT